Tag: Abeona Therapeutics (ABEO)

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics ( HALO )  announced that it will present nonclinical data at the 32 nd  Annual Meeting of the Society for Immunotherapy of Cancer (SITC) which demonstrate the potential for PEGPH20, Halozyme's pegylated recombinant human hyaluronidase, to increase the...

Read More

November 10, 2017

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

RegenxBio: Another licensing agreement providing additional validation of its NAV platform

RegenxBio (RGNX)  has granted  Abeona Therapeutics (ABEO) an exclusive worldwide license to its NAV AAV9 viral vector (subject to certain non-exclusive rights previously granted for MPS IIIA) for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA) and type B...

Read More

November 5, 2018

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

Search ProhostBiotech